ACER Stock Price, Chart, Stats & News
Acer Therapeutics Inc. (ACER) does not currently pay a dividend.
ACER chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -6.19% |
ROA | -225.71% |
ROE | 283.88% |
D/E | -0.71x |
Interest coverage ratio | -242.67x |
ACER valuation
P/E | – |
P/S | – |
P/B | -0.62x |
P/CF | -0.34x |
P/FCF | – |
P/OCF | -0.34x |
PEG | -0.00x |
EV multiple | 0.39x |
About
Acer Therapeutics Inc. is a pharmaceutical company dedicated to acquiring, developing, and commercializing treatments for severe rare and life-threatening conditions. Its clinical-stage pipeline features four key candidates: EDSIVO, for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a sodium phenylbutyrate formulation addressing inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant), designed to manage induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy showing promise against various infectious diseases, including COVID-19. The company also collaborates with the National Center for Advancing Translational Sciences (NCATS) on developing emetine hydrochloride for COVID-19 and holds worldwide licensing rights for osanetant, a selective NK3 receptor antagonist, through an agreement with Sanofi.
Similar securities
Based on sector and market capitalization
